{
    "2019-08-28": [
        [
            {
                "time": "2023-10-01",
                "original_text": "J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?",
                "features": {
                    "keywords": [
                        "J&J",
                        "landmark opioid case",
                        "pharmaceuticals"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo",
                "features": {
                    "keywords": [
                        "Ionis",
                        "out-licenses",
                        "Hepatitis B Virus",
                        "Glaxo"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "AstraZeneca's Fasenra Gets Orphan Drug Status for New Disease",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Fasenra",
                        "Orphan Drug Status",
                        "new disease"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}